HAVCR2 and non-small cell lung carcinoma: Moreover, increased serum levels of soluble TIM-3 (sTIM-3) have been detected in NSCLC patients who fail to respond to αPD-1 therapy, suggesting its potential role as a biomarker of primary immune resistance and its capacity to mediate immunosuppression through mechanisms independent of membrane-bound TIM-3 (39).